Philips and Glygenix Therapeutics to Develop Ultrasound-Mediated Gene Therapy

Philips Healthcare (Best, The Netherlands) and GlyGenix Therapeutics, Inc. (Woodbridge, CT, USA) announced a joint research agreement to research the feasibility of using ultrasound technologies for gene therapy. In particular, the collaboration will explore the treatment of glycogen storage disease-type 1a (GSD-1a) in preclinical studies.

The collaboration unites Philips' expertise in medical imaging technologies for diagnosis and minimally invasive medical procedures with GlyGenix's expertise in correcting the genetic defect in GSD-1a. "The potential to deliver genes using a targeted approach will be a significant advance for correcting genetic defects and could offer the prospect of curing hereditary diseases such as GSD-1a,” commented William Fodor, CSO of GlyGenix Therapeutics. "Philips' ultrasound-mediated DNA delivery techniques offer the opportunity to deliver genes without the size constraints and limitations of viral packaging systems, and thus open the door to the development of more robust and effective therapeutic genes.”

"Medical imaging systems already play a crucial role in minimally-invasive medical procedures such as opening obstructed arteries, correcting heart rhythm disorders, or sampling tissue biopsies of suspected lesions,” said Henk van Houten, senior vice president of Philips Research and head of the healthcare research program. "The development of ultrasound techniques that could noninvasively target the delivery of drugs, genes, and stem cells to specific parts of the body opens up further possibilities to advance patient care.”

GSD-1a is an inherited disease that makes it impossible for the body to regulate blood sugar (glucose) levels, due to a defective G6Pase gene that prevents the body from producing an enzyme called glucose-6-phosphatase. Although it is a rare disease, only affecting approximately 1 in every 100,000-200,000 births in the United States alone, it results in a significant reduction in patients' quality of life and can lead to potentially life-threatening comorbidities in early adulthood. Currently, there are no approved curative treatments for GSD-1a. Correcting the genetic defect that causes it could offer the prospect of an effective therapy that would allow patients with GSD-1a to lead a normal life.

Current gene therapies that rely solely on the bloodstream to deliver corrective gene molecules typically fail to deliver sufficient quantities to the target organs. However, by directing focused ultrasound to target organs following DNA delivery, an increase in uptake via a process known as sonoporation has been successfully demonstrated in pre-clinical studies. Sonoporation increases the permeability of cell walls to allow the uptake of large molecules, thereby enabling the delivery of therapeutic genes.

Compared to current gene therapies that use viral vectors to infect cells, this ultrasound-mediated technique carries no risk of an antiviral immune or inflammatory response. In addition, this targeted approach could reduce side effects.

The proposed treatment is known as ultrasound-mediated plasmid DNA (pDNA) delivery. The research program into it will specifically target the expression of a functional human G6Pase therapeutic pDNA to the liver, the primary organ responsible for glycogen storage and glucose release. Preclinical studies to investigate the feasibility of the technique will be performed by Philips Research and GlyGenix Therapeutics in collaboration with the Duke University School of Medicine's division of medical genetics (Durham, NC, USA), a recognized leader in GSD-1a diagnosis, managed care, pediatric genetics, and experimental models.

GlyGenix Therapeutics holds a worldwide exclusive license to the G6Pase gene, protein, and related mutations for the treatment of GSD-1a. GlyGenix will seek to obtain orphan drug designation for the treatment of GSD-1a, which would provide seven years of market exclusivity.

GlyGenix Therapeutics is a privately held biotech company developing therapeutic solutions for severe metabolic disorders. The company's initial focus is in using gene therapy products with nonviral delivery systems for the treatment of GSD1a, a rare and severe chronic genetic liver disease for which no approved therapies exist. With the aid of a sizable body of preclinical data, GlyGenix Therapeutics, Inc is poised to expedite the initiation of clinical trials for the treatment of GSD1a.

Related Links:
Philips Healthcare
GlyGenix Therapeutics